AdaptResponse - LEADconnection

AdaptResponse

Posted on September 29th, 2022
Bookmark
ClosePlease login

The purpose of AdaptResponse was to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Results presented at the European Heart Rhythm Association (EHRA) 2023. Publication pending.

Link to ClinicalTrials.gov for study description.

Other resources:

View the Radcliff Cardiology presentation recorded at EHRA 2023.

Press release: AdaptResponse Study Results Presented as Late Breaking Science at European Heart Rhythm Association (EHRA) 2023, Medtronic News, April 17, 2023

Bookmark
ClosePlease login

The purpose of AdaptResponse was to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Results presented at the European Heart Rhythm Association (EHRA) 2023. Publication pending.

Link to ClinicalTrials.gov for study description.

Other resources:

View the Radcliff Cardiology presentation recorded at EHRA 2023.

Press release: AdaptResponse Study Results Presented as Late Breaking Science at European Heart Rhythm Association (EHRA) 2023, Medtronic News, April 17, 2023